Shadi Nahvi1,2, Tangeria R Adams1, Yuming Ning, Chenshu Zhang1, Julia H Arnsten1,2,3. 1. Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA. 2. Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA. 3. Department of Epidemiology and Population Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA.
Abstract
BACKGROUND AND AIMS: Level of adherence to tobacco cessation medication regimens is believed to be causally related to medication effectiveness. This study aimed to evaluate the efficacy of varenicline directly observed therapy (DOT) on varenicline adherence and smoking cessation rates among smokers with opioid use disorder (OUD) receiving methadone treatment. DESIGN: Multicenter, parallel-group two-arm randomized controlled trial. SETTING: Urban opioid treatment program (OTP) in the Bronx, New York, USA. PARTICIPANTS: Daily smokers of ≥ 5 cigarettes/day, interested in quitting (ladder of change score 6-8), in methadone treatment for ≥ 3 months, attending OTP ≥ 3 days/week. Participants' mean age was 49 years, 56% were male, 44% Latino, 30% Black, and they smoked a median of 10 cigarettes/day. INTERVENTIONS: Individual, block, random assignment to 12 weeks of varenicline, either directly observed with methadone (DOT, n = 50) or via unsupervised self-administered treatment (SAT, n = 50). MEASUREMENTS: The primary outcome was adherence measured by pill count. The secondary outcome was 7-day point prevalence tobacco abstinence verified by expired carbon monoxide (CO) < 8 parts per million. FINDINGS: Retention at 24 weeks was 92%. Mean adherence was 78.5% [95% confidence interval (CI) = 71.8-85.2%] in the DOT group versus 61.8% in the SAT group (95% CI = 55.0-68.6%); differences were driven by DOT effects in the first 6 weeks. CO-verified abstinence did not differ between groups during the intervention (P = 0.26), but was higher in the DOT than the SAT group at intervention end (DOT = 18% versus SAT = 10%, difference = 8%, 95% CI = -13, 28); this difference was not significant (P = 0.39) and was not sustained at 24-week follow-up. CONCLUSIONS: Among daily smokers attending opioid treatment programs, opioid treatment program-based varenicline directly observed therapy was associated with early increases in varenicline adherence compared with self-administered treatment, but findings were inconclusive as to whether directly observed therapy was associated with a difference in tobacco abstinence.
BACKGROUND AND AIMS: Level of adherence to tobacco cessation medication regimens is believed to be causally related to medication effectiveness. This study aimed to evaluate the efficacy of varenicline directly observed therapy (DOT) on varenicline adherence and smoking cessation rates among smokers with opioid use disorder (OUD) receiving methadone treatment. DESIGN: Multicenter, parallel-group two-arm randomized controlled trial. SETTING: Urban opioid treatment program (OTP) in the Bronx, New York, USA. PARTICIPANTS: Daily smokers of ≥ 5 cigarettes/day, interested in quitting (ladder of change score 6-8), in methadone treatment for ≥ 3 months, attending OTP ≥ 3 days/week. Participants' mean age was 49 years, 56% were male, 44% Latino, 30% Black, and they smoked a median of 10 cigarettes/day. INTERVENTIONS: Individual, block, random assignment to 12 weeks of varenicline, either directly observed with methadone (DOT, n = 50) or via unsupervised self-administered treatment (SAT, n = 50). MEASUREMENTS: The primary outcome was adherence measured by pill count. The secondary outcome was 7-day point prevalence tobacco abstinence verified by expired carbon monoxide (CO) < 8 parts per million. FINDINGS: Retention at 24 weeks was 92%. Mean adherence was 78.5% [95% confidence interval (CI) = 71.8-85.2%] in the DOT group versus 61.8% in the SAT group (95% CI = 55.0-68.6%); differences were driven by DOT effects in the first 6 weeks. CO-verified abstinence did not differ between groups during the intervention (P = 0.26), but was higher in the DOT than the SAT group at intervention end (DOT = 18% versus SAT = 10%, difference = 8%, 95% CI = -13, 28); this difference was not significant (P = 0.39) and was not sustained at 24-week follow-up. CONCLUSIONS: Among daily smokers attending opioid treatment programs, opioid treatment program-based varenicline directly observed therapy was associated with early increases in varenicline adherence compared with self-administered treatment, but findings were inconclusive as to whether directly observed therapy was associated with a difference in tobacco abstinence.
Authors: Saul Shiffman; Christine T Sweeney; Stuart G Ferguson; Mark A Sembower; Joseph G Gitchell Journal: Clin Ther Date: 2008-10 Impact factor: 3.393
Authors: Sophia S C Chan; Doris Y P Leung; Abu S M Abdullah; Sue S T Lo; Andrew W C Yip; Wai-Ming Kok; Sai-Yin Ho; Tai-Hing Lam Journal: Am J Prev Med Date: 2010-09 Impact factor: 5.043
Authors: Robert A Schnoll; Patricia M Goelz; Anna Veluz-Wilkins; Sonja Blazekovic; Lindsay Powers; Frank T Leone; Peter Gariti; E Paul Wileyto; Brian Hitsman Journal: JAMA Intern Med Date: 2015-04 Impact factor: 21.873
Authors: Shadi Nahvi; Bryan Wu; Kimber P Richter; Steven L Bernstein; Julia H Arnsten Journal: Drug Alcohol Depend Date: 2013-01-17 Impact factor: 4.492
Authors: Duncan Smith-Rohrberg Maru; Robert Douglas Bruce; Mary Walton; Sandra A Springer; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2009-02-01 Impact factor: 3.731
Authors: Elizabeth S Hawes; Sofía Mildrum Chana; Alexandra Faust; Julianne C Baker; Peter S Hendricks; Andres Azuero; Adrienne C Lahti; Matthew J Carpenter; Karen L Cropsey Journal: Front Psychiatry Date: 2022-06-21 Impact factor: 5.435